TherapeuticsMD, Inc. (TXMD) intrinsic value & 10-year financials
TherapeuticsMD, Inc. (TXMD) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue shrank 18.6% a year to $3.0M, with an average return on invested capital of -248.7%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $1.90
- Market cap
- $22.0M
- Revenue (FY2025)
- $3.0M
- Revenue growth (10-yr CAGR)
- -18.6%
- ROIC (10-yr avg)
- -248.7%
- Free cash flow (FY2025)
- —
TXMD 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $3.0M | -$569.0K | -$0.05 | — | -145.3% | -2.2% |
| FY2024 | $1.8M | -$2.2M | -$0.00 | — | -270.3% | -15.8% |
| FY2023 | $300.0K | -$10.3M | -$0.00 | — | -2841.0% | -47.2% |
| FY2022 | $70.0M | $112.0M | $0.01 | — | 1.7% | 532.9% |
| FY2021 | $87.0M | -$172.4M | -$0.02 | -$142.7M | -160.7% | -433.9% |
| FY2020 | $64.9M | -$183.5M | — | -$159.7M | -239.8% | -390.3% |
| FY2019 | $49.6M | -$176.1M | — | -$168.1M | -304.6% | -573.4% |
| FY2018 | $16.1M | -$132.6M | — | -$107.0M | -808.8% | -1427.2% |
| FY2017 | $16.8M | -$76.9M | — | -$76.2M | -462.7% | -59.8% |
| FY2016 | $19.4M | -$89.9M | — | -$69.5M | -466.3% | -70.5% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
TherapeuticsMD, Inc. is facing top-line stagnation, with revenue contracting over the decade.
TherapeuticsMD, Inc. has historically struggled to out-earn its cost of capital, averaging just -21.8% ROIC.
TherapeuticsMD, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, TherapeuticsMD, Inc. is modeled at -18.6% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-0.30 per share.